title: Reply to the letter to the editor 'Number-Needed-To-Treat for pricing costly anti-cancer drugs. The example of Regorafenib in metastatic colorectal cancer' by Graziano et al.
authors: Department of Scientific and Regulatory Management francesco.pignatti@ema.europa.eu.
authors: F
authors: F
authors: Pignatti
authors: Human Medicines R&D Support, European Medicines Agency, London, UK.
authors: J
authors: J
authors: Martinalbo
authors: Department of Clinical Evaluation, Swedish Medical Products Agency (MPA), Uppsala, Sweden.
authors: B
authors: B
authors: Jonsson
authors: Department of Authorisation, Italian Medicines Agency (AIFA), Rome, Italy.
authors: P
authors: P
authors: Foggi
mesh_terms: D000970:Antineoplastic Agents; D015179:Colorectal Neoplasms; D006801:Humans; D010671:Phenylurea Compounds; D011725:Pyridines
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib